NEWS

30

2025-10

Imviva Biotech Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA313 for Patients with Autoimmune Diseases at ACR Convergence 2025

28

2025-10

ACR 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA311 and CTA313 for Patients with Autoimmune Diseases

16

2025-06

EHA 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Universal CAR-T Therapy CTD402 for Patients with R/R T-ALL/LBL

01

2025-06

ASCO 2025 | Bioheng Therapeutics Presents Positive Clinical Data of the Universal CAR-T Product RD06-03 in R/R B-ALL

June 1, 2025 , Bioheng Therapeutics, an innovative biopharmaceutical company focused on the development and commercialization of cell therapies, presented results from an investigator-initiated trial (IIT) of RD06-03, its allogeneic anti-CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

28

2025-02

Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL

February 28, 2025 – Bioheng Therapeutics US LLC (“Bioheng”), a clinical-stage biopharmaceutical company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for CTD402, a CD7-targeted universal CAR-T (UCAR-T) cell therapy, for the treatment of pediatric and adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL). The study approved by the FDA is a single-arm, open-label Phase Ib/II trial with a simplified dose-finding design, designed to optimize dosing and accelerate clinical development.

< 1234 >

Contact Us

Consult Now